Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo may boost esophageal cancer treatment before surgery

NCT ID NCT07457528

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated May 16, 2026 · Updated 13 times

Summary

This study tests whether adding two drugs (serplulimab and nimotuzumab) to standard chemoradiation before surgery can improve outcomes for people with a certain type of esophageal cancer. About 46 adults with resectable, locally advanced esophageal squamous cell carcinoma will receive the combination therapy, then undergo surgery 6-8 weeks later. The goal is to see if this approach leads to a better response in the tumor tissue removed during surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tianjin Medical University Cancer Institute & Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA